Advertisement
January 2016

January 2016

Welcome to the January issue. Our upfront topics range from a cross-country cancer cost comparison, to details of the French cancer trial tragedy. Our feature speculates on the future of the Biopharmaceutical Industry – discussing the role of Immuno-oncology, gene editing and other emerging therapeutic techniques. In best practice, Lisa Allen discusses the approaching deadline for the European Union’s REACH regulation, in NextGen, Miguel Forte discusses the role of vendors and manufacturing organizations to cell therapies, and we Sit Down With Diane Paskiet of West Pharmaceutical Services.

Recent Issues
Advertisement